CHRS Q3 2023 Earnings — Coherus Oncology, Inc. Revenue & Financial Results | Market Cap Arena

CHRSCoherus Oncology, Inc.

$226M

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$75M+64.2% YoY

Gross Profit

$42M56.1% margin

Operating Income

-$32M-42.9% margin

Net Income

-$40M-53.2% margin

EPS (Diluted)

$-0.41

QoQ Revenue Growth

+27.0%

Cash Flow

Operating Cash Flow

-$54M

Free Cash Flow

-$54M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$584M

Total Liabilities

$717M

Stockholders' Equity

-$134M

Cash & Equivalents

$81M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$75M	$45M	+64.2%
Gross Profit	$42M	$10M	+310.8%
Operating Income	-$32M	-$80M	+60.2%
Net Income	-$40M	-$87M	+54.3%

Revenue Segments

Product Revenue

$74M100%

Other

$204,0000%